Your session is about to expire
← Back to Search
Pulmonary Suffusion for Lung Metastases
Study Summary
This trial is testing a minimally invasive way to deliver chemo drugs to lung tissues to see if it can control the spread of sarcomas.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- The investigator thinks you are not a good fit for the study drug or the way it will be given to you, based on your overall health condition.I haven't had chemotherapy or radiotherapy in the last 4 weeks, or 6 weeks for specific drugs, and have recovered from any side effects.I am able to get out of my bed or chair and move around.My primary cancer is under control as per my doctor's assessment.I can walk at least half the distance expected for someone my age and size in six minutes.I do not have any severe illnesses or social situations that would prevent me from following the study's requirements.I have sarcoma lung metastases that can be surgically removed.I have been diagnosed with colorectal cancer.I have been diagnosed with soft tissue sarcoma.You use oxygen at home.I do not have brain metastases.You have taken a new medication being tested in a clinical trial within the last month.My oxygen levels stay above 88% whether I'm moving or resting.My lung cancer spread cannot be fully removed or treated with surgery.You can't have difficulty breathing rated higher than a 5 on the Borg Dyspnea scale (modified).I have severe nerve pain or numbness in my hands or feet.My surgeon and radiologist agree that my procedure is possible.I have been diagnosed with osteosarcoma.
- Group 1: Prevention (cisplatin, metastasectomy)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What are the aims of this medical experiment?
"Over the span of two years, this clinical trial will assess a recommended Phase II dosage. The primary objectives include assessing local and systemic toxicities with NCI CTCAE v5.0, disease-free survival using Kaplan-Meier methods to estimate median and 2-year survival rates with 90% confidence intervals, as well as gauging incidence of toxicity in each arm through frequencies and relative frequencies."
Are there any prior investigations regarding Isolated Chemotherapeutic Lung Perfusion?
"Presently, 746 separate clinical trials for Isolated Chemotherapeutic Lung Perfusion are ongoing. Of these studies, 289 have reached the final phase of testing. Most of these experiments take place in Shanghai; however, 44121 different sites are running trials related to this research topic."
What is the current capacity for enrolment into this research project?
"Correct. Per the information found on clinicaltrials.gov, this medical trial is currently enrolling participants which began recruitment on July 16th 2020 and was last updated November 22nd 2022. The study needs to acquire 99 patients from one center in total."
Are there any available opportunities for participants to join this experiment?
"According to clinicaltrials.gov, this medical trial is still open for enrolment. The first post was shared on July 16th 2020 and the listing has been revised as recently as November 22nd 2022."
What medical conditions is Isolated Chemotherapeutic Lung Perfusion employed to address?
"Isolated Chemotherapeutic Lung Perfusion is often utilized to treat neoplasm metastasis, but can also be beneficial in treating advanced ovarian cancer unresponsive to traditional treatments, as well as certain advance directives."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger